Every 10-Q that Avita Medical, Inc. (RCEL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCEL filings page.
AVITA Medical, Inc., a wound-care company focused on its RECELL platform, reported higher revenues but continued losses for the quarter and six-months ended June 30, 2026. Total revenues were $21,702 (in thousands) for the quarter and $40,953 (in thousands) year-to-date, up from $18,418 and $36,932 (in thousands) a year earlier. Net loss narrowed to $7,663 (in thousands) for the quarter and $18,274 (in thousands) for six months, versus $9,920 and $23,779 (in thousands) in 2025.
As of June 30, 2026, the company had cash, cash equivalents, and marketable securities of $11.1 million and a stockholders’ deficit of $27,838 (in thousands), with a $46,659 (in thousands) loan facility recorded as a current liability. Management determined there is substantial doubt about the ability to continue as a going concern over the next twelve months, and the auditor’s review report referenced this uncertainty.
In January 2026 AVITA entered a five-year senior secured credit facility of up to $60.0 million, drawing $50.0 million and using part of the proceeds to refinance a prior loan; the interest rate was 11.5% as of June 30, 2026, and covenants include a $5.0 million minimum cash balance and net revenue tests. The company also signed a 10-year BARDA agreement providing about $4.0 million in access and maintenance fees over the term, plus potential procurement revenue, and continues to build its portfolio through Cohealyx and PermeaDerm distribution and manufacturing arrangements.
AVITA Medical, Inc. reported first-quarter 2026 revenue of $19.3 million, up modestly from $18.5 million a year earlier, driven mainly by increased contributions from Cohealyx and RECELL GO alongside stable RECELL sales.
The company posted a net loss of $10.6 million, an improvement from a $13.9 million loss in the prior-year quarter, as operating expenses declined across sales and marketing, general and administrative, and research and development. Cash, cash equivalents, and marketable securities totaled $14.3 million as of March 31, 2026, while operating activities used $10.1 million of cash in the quarter.
AVITA refinanced its prior debt with a new five-year senior secured credit facility from Perceptive Advisors, drawing $50.0 million and receiving about $6.0 million in net proceeds after repayment of the previous credit agreement and fees. The fair value of the loan facility was $46.1 million at quarter-end, and the company reported a stockholders’ deficit of $23.2 million with an accumulated deficit of $419.0 million.
Management concluded there is “substantial doubt” about AVITA’s ability to continue as a going concern over the next twelve months due to recurring losses, negative operating cash flows, and debt repayment obligations. As a result, the long-term portion of the credit facility is classified as a current liability. The company is evaluating options such as accessing an additional $10.0 million under the facility, subject to net revenue requirements, or raising equity financing.
After quarter-end, AVITA entered a ten-year agreement with BARDA with a total potential value of up to $25.5 million, including about $3.97 million in expected access and readiness fees over the term and additional procurement options. The Board also confirmed Cary Vance as President and Chief Executive Officer and appointed Jan Stern Reed as Chair of the Board.
AVITA Medical (RCEL) filed its Q3 2025 10‑Q, reporting lower revenue and a going concern warning. Total revenue was $17.1 million for the quarter, down from $19.5 million a year ago. Net loss was $13.2 million versus $16.2 million in the prior year period. For the nine months, revenue reached $54.0 million and net loss was $37.0 million.
Cash, cash equivalents, and marketable securities were $23.3 million as of September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern due to expected non‑compliance with a minimum cash covenant under its senior secured credit facility. The loan facility balance of $42.4 million was classified as current. AVITA obtained revenue covenant waivers for Q1–Q3 2025 and amended future thresholds.
To bolster liquidity, AVITA completed an August 12, 2025 private placement raising $14.8 million gross (3,440,377 common share equivalents via 17,201,886 CDIs). Shares outstanding were 30,493,111 as of November 3, 2025. Lease revenue from RECELL GO devices was $165,000 in Q3, with product sales the primary driver of revenue.